“Early-stage deals” between biotech and pharma can refer to a broad range of partnerships, from the discovery of novel targets or evaluating drug modalities, to elucidating pathways associated with certain disease pathologies, all the way to clinical candidates with safety and efficacy profiles in non-human primates. As platform and pharma companies bring their own perspectives and goals for collaboration and value creation, how can we ensure early engagement with stakeholders, as well as alignment and creativity in deal structures to deliver for both partners in their joint pursuit of biological insights or therapeutic interventions? Join Amanda Kay, Senior Partner and Chief Business Development Officer at Flagship, and a panel of biotech entrepreneurs, business development and R&D leaders from industry for a conversation to explore these topics.
